• #26: Moderna Faces Manufacturing Costs and Revenue Challenges

  • 2025/02/25
  • 再生時間： 5 分
  • ポッドキャスト

#26: Moderna Faces Manufacturing Costs and Revenue Challenges

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • In 2024, Moderna faced financial challenges including $739 million in cost of sales for the fourth quarter, which factored in $193 million in inventory write-downs, $259 million in production wind-down costs, and a $238 million charge from a cancelled contract. The company's total revenue for 2024 was $3.2 billion, a 72% decrease from the previous year. Moderna is working to resize its production footprint to meet post-pandemic needs and has struggled to accurately gauge vaccine demand in the current market. Moderna anticipates revenue between $1.5 billion and $2.5 billion in 2025.

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示

あらすじ・解説

In 2024, Moderna faced financial challenges including $739 million in cost of sales for the fourth quarter, which factored in $193 million in inventory write-downs, $259 million in production wind-down costs, and a $238 million charge from a cancelled contract. The company's total revenue for 2024 was $3.2 billion, a 72% decrease from the previous year. Moderna is working to resize its production footprint to meet post-pandemic needs and has struggled to accurately gauge vaccine demand in the current market. Moderna anticipates revenue between $1.5 billion and $2.5 billion in 2025.

Hosted on Acast. See acast.com/privacy for more information.
続きを読む 一部表示

#26: Moderna Faces Manufacturing Costs and Revenue Challengesに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。